Crossmark

: N.D.S. reports research/consulting: Allessa, Amgen, Artera, Astellas, AstraZeneca, Aura Biosciences, Bayer, Bristol Myers Squibb, Caris, CG Oncology, Daiichi Sankyo, Dendreon, Glytheryx, Invitae, Janssen, MDxhealth, Merck, Minomic, Novartis, Nusano, PhotoCure, Pfizer, Sumitomo, Telix, Tolmar, Tutelix and Urogen. T.B.P. reports honoraria: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Elexis, Gilead, Incyte, Ipsen, Johnson & Johnson, Mashup, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seagen; consulting or advisory role: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Elexis, Gilead, Incyte, Ipsen, Johnson & Johnson, Mashup, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seagen; research funding: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Elexis, Incyte, Ipsen, Johnson & Johnson, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seagen; and travel, accommodations or expenses: Astellas, AstraZeneca, Gilead, Ipsen, Merck Sharp & Dohme, Pfizer and Roche. J. Bedke reports financial interests from Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Ipsen, Janssen, Merck Sorono, Merck Sharp & Dohme, Pfizer, Roche, Nektar, Novartis and Seagen and membership in the European Association of Urology and the Renal Cell Carcinoma Guidelines Panel (Vice-Chairman). M.D.G. reports stock and other ownership interests: Pfizer, Merck and Gilead Sciences; research funding: Merck, Bristol Myers Squibb, Mirati Therapeutics, Seagen, Alliance Foundation Trials, Alliance for Clinical Trials in Oncology, Clovis Oncology, Arvinas, ALX Oncology, Hoosier Cancer Research Network, Novartis, Acrivon Therapeutics, Astellas, Genentech, Accuray, PCCTC, G1 Therapeutics, OncoC4, Flare Therapeutics, Loxo/Lilly, Roche and Pfizer; other relationships: Elsevier, Medscape and Research to Practice; uncompensated relationships: G1 Therapeutics and Loxo/Lilly. J.P.R. reports advisory/consultancy roles for Arquer Diagnostics, Biotech, BTA Pharmaceuticals, Combat, Genomic Expression and Olympus; steering committee membership for AstraZeneca, Bristol Myers Squibb, Janssen and Pfizer; grant or research support from Arquer Diagnostics, Biotech, BTA Pharmaceuticals, Cepheid, TARIS Biomedical and Nucleix; and research funding from Pfizer. J.H.K. reports research funding from Pfizer. M.K. reports research funding from Pfizer. E.X. reports consulting or advisory role: Pfizer, Ferring and Boston Scientific and research funding: Ferring and Pfizer. B.A. reports honoraria: AstraZeneca, Astellas, Eisai, Janssen, Bayer, Merck Sharp & Dohme, Merck, Pfizer, Roche and Bristol Myers Squibb; consulting or advisory role: AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Janssen, Merck, Pfizer, Merck Sharp & Dohme, Roche and Eisai; speakers’ bureau: Janssen, Astellas, Pfizer, AstraZeneca, Bayer, Merck, Bristol Myers Squibb, Merck Sharp & Dohme, Eisai and Roche; research funding: AstraZeneca, Merck, Bayer, Astellas, Janssen, Bristol Myers Squibb, Pfizer, ICON Clinical Research, Eisai, Merck Sharp & Dohme and Roche; and travel, accommodations and expenses: AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Janssen, Merck Sharp & Dohme, Pfizer and Sanofi. D.Y. reports research funding from Pfizer. F.G.-R. reports research support/principal investigator: Johnson & Johnson, Pfizer, Taris, Bristol Myers Squibb, Roche, Seagen, AstraZeneca, Combat Medical, Cepheid, Fidia, Astellas, UroGen and Merck Sharp & Dohme; employment: SERMAS (Servicio Madrileño de Salud); consultancy: Johnson & Johnson, Pfizer, Merck, Roche, Taris, Combat Medical, AstraZeneca, Merck Sharp & Dohme and Bristol Myers Squibb; stockholder: CG Oncology; speakers’ bureau: Janssen, Nucleix, Merck Sharp & Dohme, Pfizer, Merck, Bristol Myers Squibb, AstraZeneca, Palex, Combat Medical, Johnson & Johnson and Recordati; travel: Pfizer, Recordati, Ipsen, Combat Medical, Alter, Salvat, Nucleix, AstraZeneca, Fidia and Johnson & Johnson; advisory board: AstraZeneca, Bristol Myers Squibb, Combat Medical, Johnson & Johnson, Nucleix, Pfizer, Taris, Roche and Merck Sharp & Dohme; and manuscript support: Pfizer, Janssen, Combat Medical, AstraZeneca, Johnson & Johnson and Bristol Myers Squibb. A.B. reports consulting or advisory role: Astellas, Janssen-Cilag, OPKO Health, MDxHealth, Ferring, Bayer, AstraZeneca, Hauora and Pfizer; speakers’ bureau: Astellas; and research funding: Sandoz-Novartis, Merck Sharp & Dohme and Pfizer. G.S.K. reports honoraria: AbbVie, Tersera, Bayer, Knight Pharmaceuticals, AstraZeneca Canada and PhotoCure; consulting or advisory role: Merck, Theralase, Janssen Oncology, Ferring, Verity Pharmaceuticals, Bristol Myers Squibb, EMD Serono, Pfizer, Novartis and enGene; research funding: Johnson & Johnson/Janssen and Pfizer. J. Brinkmann reports employment: Pfizer Pharma GmbH. A.-M.C. reports employment: Pfizer SRL. R.C. reports employment: Pfizer SRL. A.E. reports employment: Pfizer Ltd. E.M. reports employment: Pfizer Inc. J.V. reports employment: Pfizer Inc. C.W. reports employment: Pfizer Inc. G.D.S. reports advisory/consultancy roles: Heat Biologics, CG Oncology, PhotoCure, Merck, Roche/Genentech, Ciclomed, Taris Biomedical (now Janssen), MDxHealth, Fidia Farmaceutici, UroGen, Ferring, Aduro, Boston Scientific, Bristol Myers Squibb, AstraZeneca, Pfizer, Janssen, Epivax Therapeutics, Natera, FKD, EnGene Bio, Sesen Bio, BioCanCell (now Archiano), Nucleix, Ipsen, Combat Medical, Astellas, FerGene, Dendreon, AbbVie, Seagen, Verity Pharmaceuticals, Regeneron, STIMIT, Vyriad, Protara, xCures, Nonagen, Nanology and Imvax; clinical trial protocol committee membership for Bristol Myers Squibb, CG Oncology, Fidia, Janssen, Merck, Pfizer, PhotoCure, Protara and Seagen; stock/shares in CG Oncology, EnGene Bio, EpiVax Therapeutics and UroGen; and research funding from Pfizer.

Document is current

Any future updates will be listed below